Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta‐analysis
Authors' conclusion
Survodutide significantly reduced HbA1c, body weight, and waist circumference. A greater reduction in HbA1c was specifically associated with a higher total weekly dose (>2.4 mg), while more pronounced effects on body weight and waist circumference were observed with both higher doses and longer treatment durations (>16 weeks). However, it is crucial to highlight the significant increase in gastrointestinal AEs and the associated risk of treatment discontinuation. Further large-scale, multicentre, long-term, and high-quality RCTs are necessary to validate these results in diverse populations.
Study context
- Population
- Adults; Randomized Controlled Trials (RCTs) of survodutide up to 12 July 2025
- Participants
- 1,272 adults6 RCTs
- Comparison
- Survodutide vs placebo
- Outcome
- Changes in HbA1c, fasting glucagon, body weight, waist circumference, and incidence of AEs
Pooled result
As reported in the abstract
Further pooled results
Dose and duration subgroups
- Greater HbA1c and fasting glucagon reductions with total weekly dose >2.4 mg vs ≤2.4 mg
- Greater body weight and waist circumference effects with higher weekly doses (>2.4 mg) and longer treatment (>16 weeks)
Body mass index (BMI), lipids, blood pressure
- Significant reductions in BMI; modest reductions in total cholesterol, TG and blood pressure
Safety
- Higher risk of treatment discontinuation due to adverse events (AEs) with survodutide; gastrointestinal AEs most common
- No significant increase in serious AEs
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →